Journal of Internal Medicine 1989; **226**: 465–468

Author Index

Aberg H & Tibblin G. Addition of non-pharmacological methods of treatment in patients on antihypertensive drugs: results of previous medication, laboratory tests and life quality, 39
Achten E, *see* Spapen HDM *et al.*, 465
Agardh C-D, *see* Agardh E *et al.*, 47
Agardh E, Torffvit O & Agardh C-D. The prevalence of retinopathy and associated medical risk factors in type I (insulin-dependent) diabetes mellitus, 47
Ahnve S, Angelin B, Edhag O & Berglund L. Early determination of serum lipids and apolipoproteins in acute myocardial infarction: possibility for immediate intervention, 297
Alam M, *see* Höglund C *et al.*, 251
Alam M, Rosenhamer G & Höglund C. Comparability of echocardiography and chest X-ray following myocardial infarction, 171
Alverstrand A, *see* Stenvinkel P *et al.*, 183
Alvestrand A, *see* Bergström J *et al.*, 189
Andersen PT, Nielsen LK, Hansen AK, Toft E & Jensen BV. Serum and urinary phosphate during and after prolonged muscular ischaemia in non-exercising men and women, 149
Andersson OK, Beckmann-Suurküla M, Sannerstedt R, Magnusson M & Sivertsson R. Does hyperkinetic circulation constitute a pre-hypertensive stage? A 5-year follow-up of haemodynamics in young men with mild blood pressure elevation, 401
Angelin B, *see* Ahnve S *et al.*, 297
Angelin B, *see* Löfberg R *et al.*, 157
Angelo Bonati P, *see* Zavaroni I *et al.*, 417
Ankier SI & Warrington SJ. A double-blind placebo-controlled study of the efficacy and tolerability of ebastine against hayfever in general practice patients, 453
Aoki T, *see* Heinemann L *et al.*, 325
Appleyard M, *see* Lange P *et al.*, 25
Arjona R, *see* Riancho JA *et al.*, 449
Aro A, Pietinen P, Uusitalo U & Tuomilehto J. Coffee and tea consumption, dietary fat intake and serum cholesterol concentration of Finnish men and women, 127
Asplund A, *see* Carlson LA *et al.*, 271
Ásvaldsdóttir H, *see* Hardarson T *et al.*, 33
Avvisati G, *see* Petrucci MT *et al.*, 443

Baehrendtz S, *see* Höjer J *et al.*, 117
Bake B, *see* Caidahl K *et al.*, 265
Baynes RD, *see* Bothwell TH *et al.*, 357
Beckmann-Suurküla M, *see* Andersson OK *et al.*, 401
Bengtsson B-Å, *see* Landin K *et al.*, 205
Benn J, *see* Heinemann L *et al.*, 325
Berger M, *see* Heinemann L *et al.*, 325
Berglund L, *see* Ahnve S *et al.*, 297
Bergman L, *see* Sjölund K *et al.*, 133
Bergonzani M, *see* Zavaroni I *et al.*, 417
Bergström J, *see* Stenvinkel P *et al.*, 183
Bergström J, Alvestrand A, Fürst P & Lindholm B. Sulphur amino acids in plasma and muscle in patients with chronic renal failure: evidence for taurine depletion, 189
Berntorp E, *see* Berntorp K *et al.*, 73
Berntorp K, Ekman M & Berntorp E. Cigarette smoke impairment of human lymphocyte function by inhibition of transglutaminase, 73
Bilo HJG, *see* Stoof TJ *et al.*, 437
Binder C, *see* Melchior T *et al.*, 53
Björvell H & Hylander B. Functional status and personality in patients on chronic dialysis, 319
Bonnevie O, *see* Jess P *et al.*, 395
Bonora E, *see* Zavaroni I *et al.*, 417
Boström P-A, Johansson BW, Lecerof H, Lilja B & Torp A. Effect of xamaterol on exercise capacity and left ventricular function in angina pectoris and in dilated cardiomyopathy, 331
Bothwell TH, Baynes RD, MacFarlane BJ & MacPhail AP. Nutritional iron requirements and food iron absorption, 357
Böttinger LE. The editorial policy of *JIM*, 71
Brørs O, *see* Theodorsen L, 17
Bugge PM, *see* Gjørup T *et al.*, 123
Buonanno G, *see* Zavaroni I *et al.*, 417
Butturini L, *see* Zavaroni I *et al.*, 417

Caidahl K, Lurie M, Bake B, Johansson G & Wetterqvist H. Dyspnoea in chronic primary fibromyalgia, 265
Carlson LA, Hamsten A & Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid, 271
Christensen JH, Freundlich M, Jacobsen BA & Falstie-Jensen N. Clinical revelance of pedal pulse palpation in patients suspected of peripheral arterial insufficiency, 95
Christensen T, *see* Eiskjær H *et al.*, 235
Christiansen PM, *see* Jess P *et al.*, 395
Cook JD & Skikne BS. Iron deficiency: definition and diagnosis, 349
Coughlan G, *see* Ryan T *et al.*, 277

Dallman PR. Iron deficiency: does it matter? 367
Davidsen B, Egeblad H. & Pietersen A. Thromboembolism in patients with advanced mitral valve prolapse, 433
de Geeter F, *see* Spapen HDM *et al.*, 463
Defer G, *see* Zuber M *et al.*, 291
Dejgård A, *see* Jess P *et al.*, 395
Dirksen A, *see* Groth S *et al.*, 341
Ditzel J, *see* Lervang H-H *et al.*, 261
Divine M, *see* Zuber M *et al.*, 291
Djursing H, *see* Grinsted L *et al.*, 241
Donker AJM, *see* Stoof TJ *et al.*, 437
Dupont AG, *see* Spapen HDM *et al.*, 463
Dyerberg J, *see* Sørensen PJ *et al.*, 101

Edhag O, *see* Ahnve S *et al.*, 297
Edvinsson L, *see* Sjögren A *et al.*, 213
Edwards CQ, Griffen LM, Kaplan J & Kushner JP. Twenty-four hour variation of transferrin saturation in treated and untreated haemochromatosis homozygotes, 373
Egeblad H, *see* Davidsen B *et al.*, 433
Einarsson K, *see* Löfberg R *et al.*, 157
Eiskjær H, Christensen T & Pedersen EB. Abnormal structure and increased stiffness of the femoral arterial wall in young patients with sustained essential hypertension, 235

Ekman M, *see* Berntorp K *et al.*, 73
Ekstrand A, *see* Rosenlöf K *et al.*, 311
Eriksson C-G, *see* Odar-Cederlöf I *et al.*, 177
Eskildsen PC, *see* Snorgaard O *et al.*, 223

Faergeman O, *see* Husted SE *et al.*, 303
Fallgren B, *see* Sjögren A *et al.*, 213
Falstie-Jensen N, *see* Christensen JH *et al.*, 95
Ferriss JB, *see* O'Mahony D *et al.*, 63
Finch C. New perspectives on iron in clinical medicine. Introduction: Knights of the oval table, 345
Fioramonti J, *see* Pienkowski P *et al.*, 423
Freundlich M, *see* Christensen JH *et al.*, 95
Frexinos J, *see* Pienkowski P *et al.*, 423
Fritz-Hansen P, *see* Keller N *et al.*, 195
Fürst P, *see* Bergström J *et al.*, 189
Fushimi H, Kameyama M & Shinkai H. Deficiency of the core proteins of dermatan sulphate proteoglycans in a variant form of Ehlers-Danlos syndrome, 409
Fyhrquist F, *see* Rosenlöf K *et al.*, 311
Fyhrquist F, Karppinen K, Honkanen T, Saijonmaa O & Rosenlöf K. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril, 257
Gabrielsson N, *see* Löfberg R *et al.*, 157
Gaulard P, *see* Zuber M *et al.*, 291
Gerich J, *see* Heinemann L *et al.*, 325
Gherardi R, *see* Zuber M *et al.*, 291
Giovangrossi P, *see* Petrucci MT *et al.*, 443
Gjørup T, Hendriksen C, Bugge PM & Jensen AM. Global assessment of patients—a bedside study. I: the influence of physical findings on the global assessment, 123
Gnudi L, *see* Zavaroni I *et al.*, 417
González-Macías J, *see* Riancho JA *et al.*, 449
Gribnau FWJ, *see* Koopmans PP *et al.*, 139
Griffen LM, *see* Edwards CQ *et al.*, 373
Grinsted L, Heltberg A, Hagen C & Djursing H. Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis, 241
Grönhagen-Riska C, *see* Rosenlöf K *et al.*, 311
Groth S, *see* Lange P *et al.*, 25
Groth S, Petersen C, Dirksen A & Parving H-M. Monitoring kidney function in diabetic nephropathy, 341
Grundy SM, *see* Vega CL, 5
Gustafsson L, *see* Höjer J *et al.*, 117

Hagen C, *see* Grinsted L *et al.*, 241
Hallberg L. Iron in clinical medicine—an update, 281
Hamsten A, *see* Carlson LA *et al.*, 271
Hansen AK, *see* Andersen PT *et al.*, 149
Hardarson T, Kristinsson Á, Skúladóttir G, Ásvaldsdóttir H & Snorrason SP. Cod liver oil does not reduce ventricular extrasystoles after myocardial infarction, 33
Heinemann L, Sonnenberg GE, Hohmann A, Ritzenhoff A, Berger M, Benn J, Sönksen P, Kelley D, Gerich J, Aoki T & Sorensen J. Pulsatile insulin infusion and glucose-homeostasis in well-controlled Type 1 (insulin-dependent) diabetic patients, 325
Heltberg A, *see* Grinsted L *et al.*, 241
Hendriksen C, *see* Gjørup T *et al.*, 123
Henriksen O, *see* Keller N *et al.*, 195
Höglund C, *see* Alam M *et al.*, 171
Höglund C, Alam M & Thorstrand C. Effects of acute myocardial infarction on the displacement of the atrioventricular plane: an echocardiographic study, 251
Hohmann A, *see* Heinemann *et al.*, 325
Høigaard L, *see* Jess P *et al.*, 395
Höjer J, Baehrendtz S & Gustafsson L. Benzodiazepine poisoning: experience of 702 admissions to an intensive care unit during a 14-year period, 117
Honkanen E, *see* Rosenlöf K *et al.*, 311
Honkanen T, *see* Fyhrquist F *et al.*, 257
Huikuri H, *see* Poukkula A *et al.*, 229
Huikuri HV, *see* Juhani Airaksinen KE *et al.*, 245
Hulsmans RFHG, *see* Stoof TJ *et al.*, 437
Husted SE, Kraemmer Nielsen H, Krusell LR & Faergeman O. Acetylsalicylic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo-controlled trial, 303
Hylander B, *see* Björvell H, 319

Ikäheimo M, *see* Lilja M *et al.*, 143
Ikäheimo MJ, *see* Juhani Airaksinen KE *et al.*, 245

Jacobsen BA, *see* Christensen JH *et al.*, 95
Jacobsen BA, *see* Lund L *et al.*, 201
Jalkanen L, Tuomilehto J, Nissinen A & Puska P. Changes in body mass index in a Finnish population between 1972 and 1982, 163
Jensen AM, *see* Gjørup T *et al.*, 123
Jensen BV, *see* Andersen PT *et al.*, 149
Jensen G, *see* Lange P *et al.*, 25
Jenum P, *see* Talstad I *et al.*, 459
Jess P, Von der Lieth L, Matzen P, Madsen P, Krag E, Knigge U, Høigaard L, Dejgård A, Christiansen PM & Bonnevie O. The personality pattern of duodenal ulcer patients in relation to spontaneous ulcer healing and relapse, 395
Johannessen AC, *see* Melchior T *et al.*, 53
Johansson BW, *see* Böstrom P-A *et al.*, 331
Johansson G, *see* Caidahl K *et al.*, 265
Jounela AJ, *see* Lilja M *et al.*, 143
Juhani Airaksinen KE, Ikäheimo MJ, Huikuri HV, Koistinen MJ, Linnaluoto M & Takkunen JT. Effects of isometric exercise and heart rate on left ventricular filling pattern assessed by pulsed Doppler echocardiography, 245
Juustila H, *see* Lilja M *et al.*, 143

Kameyama M, *see* Fushimi H *et al.*, 409
Kaplan J, *see* Edwards CQ *et al.*, 373
Karppinen K, *see* Fyhrquist F *et al.*, 257
Keller N, Møgelvang J, Saunamäki K, Fritz-Hansen P, Sykulski R & Henriksen O. Determinants of atrial natriuretic factor levels in coronary heart disease: significance of central pressures, heart chamber volumes and left ventricular mass, 195
Kelley D, *see* Heinemann L *et al.*, 325
Keppens C, *see* Spapen HDM *et al.*, 463
Kjellstrand CM, *see* Odar-Cederlöf I *et al.*, 177
Knigge U, *see* Jess P *et al.*, 395
Knudsen F, *see* Sørensen PJ *et al.*, 101
Knutsson A. Relationships between serum triglycerides and γ-glutamyltransferase among shift and day workers, 337
Koistinen MJ, *see* Juhani Airaksinen KE *et al.*, 245
Koopmans PP, Van Megen T, Thien T & Gribnau FWJ. The interaction between indomethacin and captopril or enalapril in healthy volunteers, 139
Korhonen UR, *see* Poukkula A *et al.*, 229
Korstanje MJ, *see* Stoof TJ *et al.*, 437
Kraemmer Nielsen H, *see* Husted SE *et al.*, 303
Krag E, *see* Jess P *et al.*, 395
Kristinsson Á, *see* Hardarson T *et al.*, 33

Krusell LR, *see* Husted SE *et al.*, 303
Kushner JP, *see* Edwards CQ *et al.*, 373

Landin K, Bengtsson B-Å & Wilhelmsen L. Addison's disease, malignant lymphoma and death from cerebral giant cell arteritis, 205
Landsfeldt U, *see* Mathiassen B *et al.*, 113
Lange P, Groth S, Nyboe J, Appleyard M, Mortensen J, Jensen G & Schnohr P. Chronic obstructive lung disease in Copenhagen: cross-sectional epidemiological aspects, 25
Larsen JK & Melgaard B. Simultaneous neuroinfection with cytomegalovirus and herpes simplex virus in an immunocompetent adult, 59
Lecerof H, *see* Böstrom P-A *et al.*, 331
Leppälueto J, *see* Lilja M *et al.*, 143
Lervang H-H, Møller-Petersen J & Ditzel J. Serum β_2-microglobulin levels in thryoid diseases, 261
Lilja B, *see* Böstrom P-A *et al.*, 331
Lilja M, Ikäheimo M, Juustila H, Pirttiaho H, Pakarinen A, Leppälueto J, Jounela AJ & Ruskoaho H. Abrupt change from a β-adrenoceptor blocking drug to enalapril in hypertension, 143
Linde A, *see* Talstad I *et al.*, 459
Lindholm B, *see* Bergström J *et al.*, 189
Linnaluoto M, *see* Juhani Airaksinen KE *et al.*, 245
Linnaluoto M, *see* Poukkula A *et al.*, 229
Löfberg R, Angelin B, Einarsson K, Gabrielsson N & Öst L. Unsatisfactory effect of cyclosporin A treatment in Crohn's disease: a report of five cases, 157
Luchetti L, *see* Zavaroni I *et al.*, 417
Lund L, Jacobsen BA & Schmidt EB. The occurrence of malignant disease in adult nephrotic syndrome, 201
Lurie M, *see* Caidahl K *et al.*, 265

MacFarlane BJ, *see* Bothwell TH *et al.*, 357
MacPhail AP, *see* Bothwell TH *et al.*, 357
Madsen P, *see* Jess P *et al.*, 395
Magnusson M, *see* Andersson OK *et al.*, 401
Mandelli F, *see* Petrucci MT *et al.*, 443
Marckmann P. Nutritional status and mortality of patients in regular dialysis therapy, 429
Mathiassen B, Thomasen H & Landsfeldt U. An evaluation of the accuracy of clinical diagnosis at admission in a population with epidemic meningococcal disease, 113
Matzen P, *see* Jess P *et al.*, 395
McGing P, *see* Ryan T *et al.*, 277
Melchior T, Wiese Simonsen K, Johannessen AC & Binder C. Plasma zinc concentrations during the first 2 years after diagnosis of insulin-dependent diabetes mellitus: a prospective study, 53
Melgaard B, *see* Larsen JK, 59
Møgelvang J, *see* Keller N *et al.*, 195
Møller-Petersen J, *see* Lervang H-H *et al.*, 261
Mølstad P. Primary ventricular fibrillation in acute myocardial infarction, 107
Mortensen J, *see* Lange P *et al.*, 25

Nerup J, *see* Snorgaard O *et al.*, 223
Nielsen AH, *see* Sørensen PJ *et al.*, 101
Nielsen LK, *see* Andersen PT *et al.*, 149
Nielsen OJ & Thaysen JH. Response to erythropoietin in anaemic haemodialysis patients, 89
Nissinen A, *see* Jalkanen L *et al.*, 163
Norberg B. Breakthrough in microtubule research, 393
Nordøy A, *see* Ytre-Arne K, 285
Nyboe J, *see* Lange P *et al.*, 25

O'Mahony D, Ferriss JB & Perry I. Fulminant severe retinopathy in newly diagnosed diabetic without risk factors, 63
Odar-Cederlöf I, Theodorsson E, Eriksson C-G & Kjellstrand CM. Plasma concentrations of calcitonin gene-related peptide increase during haemodialysis: relation to blood pressure, 177
Olesen LL. Femoral neuropathy secondary to anticoagulation, 279
Öst L, *see* Löfberg R *et al.*, 157

Pagliara M, *see* Zavaroni I *et al.*, 417
Pakarinen A, *see* Lilja M *et al.*, 143
Parving H-H, *see* Groth S *et al.*, 341
Passeri M, *see* Zavaroni I *et al.*, 417
Pedersen EB, *see* Eiskjær H *et al.*, 235
Perry I, *see* O'Mahony D *et al.*, 63
Persson J, *see* Sjölund K *et al.*, 133
Petersen C, *see* Groth S *et al.*, 341
Petrucci MT, Avvisati G, Tribalto M, Giovangrossi P & Mandelli F. Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients, 443
Phelan D, *see* Ryan T *et al.*, 277
Pienkowski P, Fioramonti J & Frexinos J. Rectal potential differences in irritable bowel syndrome and in inflammatory bowel disease in man, 423
Pietersen A, *see* Davidsen B *et al.*, 433
Pietinen P, *see* Aro A *et al.*, 127
Piiril P, *see* Rosenlöf K *et al.*, 311
Pirttiaho H, *see* Lilja M *et al.*, 143
Poukkula A, Korhonen UR, Huikuri H & Linnaluoto M. Theophylline and salbutamol in combination in patients with obstructive pulmonary disease and concurrent heart disease: effect on cardiac arrythmias, 229
Puska P, *see* Jalkanen L *et al.*, 163

Reaven GM, *see* Zavaroni I *et al.*, 417
Reichard P & Rosenqvist U. Nephropathy is delayed by intensified insulin treatment in patients with insulin-dependent diabetes mellitus and retinopathy, 81
Riancho JA, Arjona R, Valle R, Sanz J & González-Macías J. The clinical spectrum of hypocalcaemia associated with bone metastases, 449
Riis P. The scientific universe of the researcher, the media-person and the politician, 137
Ritzenhoff A, *see* Heinemann L *et al.*, 325
Rosenhamer G, *see* Alam M *et al.*, 171
Rosenlöf K, *see* Fyhrquist F *et al.*, 257
Rosenlöf K, Grönhagen-Riska C, Sovijärvi A, Honkanen E, Tikkanen I, Ekstrand A, Piiril P & Fyhrquist F. Beneficial effects of erythropoietin on haematological parameters, aerobic capacity, and body fluid composition in patients on haemodialysis, 311
Rosenqvist U, *see* Reichard P, 81
Rössner S. Weight cycling—a 'new' risk factor? 209
Ruskoaho H, *see* Lilja M *et al.*, 143
Ryan T, Coughlan G, McGing P & Phelan D. Ketosis, a complication of theophylline toxicity, 277

Saijonmaa O, *see* Fyhrquist F *et al.*, 257
Sannerstedt R, *see* Andersson OK *et al.*, 401
Sanz J, *see* Riancho JA *et al.*, 449
Saunamäki K, *see* Keller N *et al.*, 195

Schmidt EJ, *see* Lund L *et al.*, 201
Schmitz O, *see* Sørensen PJ *et al.*, 101
Schnohr P, *see* Lange P *et al.*, 25
Scott H, *see* Talstad I *et al.*, 459
Shinkai H, *see* Fushimi H *et al.*, 409
Sivertsson R, *see* Andersson OK *et al.*, 401
Sjögren A, Edvinsson L & Fallgren B. Magnesium deficiency in coronary artery disease and cardiac arrhythmias, 213
Sjölund K, Persson J & Bergman L. Can villous atrophy be induced by chronic alcohol consumption? 133
Skikne BS, *see* Cook JD, 349
Skúladóttir G, *see* Hardarson T *et al.*, 33
Snorgaard O, Eskildsen PC, Vadstrup S & Nerup J. Diabetic ketoacidosis in Denmark: epidemiology, incidence rates, precipitating factors and mortality rates, 223
Snorrason SP, *see* Hardarson T *et al.*, 33
Sönksen P, *see* Heinemann L *et al.*, 325
Sonnenberg GE, *see* Heinemann L *et al.*, 325
Sorensen J, *see* Heinemann L *et al.*, 325
Sørensen PJ, Nielsen AH, Knudsen F, Schmitz O & Dyerberg J. Protein C in renal allotransplantation during the perioperative period, 101
Sovijärvi A, *see* Rosenlöf K *et al.*, 311
Spapen HDM, Achten E, de Geeter F, Keppens C & Dupont AG. Magnetic resonance imaging of the adrenal glands in the diagnosis of primary hyperaldosteronism, 463
Starink TH M, *see* Stoof TJ *et al.*, 437
Stenvinkel P, Alverstrand A & Bergström J. Factors influencing progression in patients with chronic renal failure, 183
Stoof TJ, Korstanje MJ, Bilo HJG, Starink TH M, Hulsmans RFHG & Donker AJM. Does fish oil protect renal function in cyclosporin-treated psoriasis patients? 437
Sykulski R, *see* Keller N *et al.*, 195

Takkunen JT, *see* Juhani Airaksinen KE *et al.*, 245
Talstad I, Scott H, Jenum P & Linde A. Chronic infectious mononucleosis: a case report, 459
Thaysen JH, *see* Nielsen OJ, 89
Theodorsen L & Brørs O. The importance of lipid solubility and receptor selectivity of β-adrenoceptor blocking drugs for the occurrence of symptoms and side-effects in out-patients, 17
Theodorsson E, *see* Odar-Cederlöf I *et al.*, 177
Thien T, *see* Koopmans PP *et al.*, 139
Thomasen H, *see* Mathiassen B *et al.*, 113
Thorstrand C, *see* Höglund C *et al.*, 251
Tibblin G, *see* Aberg H, 39
Tikkanen I, *see* Rosenlöf K *et al.*, 311
Toft E, *see* Andersen PT *et al.*, 149
Torffvit O, *see* Agardh E *et al.*, 47
Torp A, *see* Böstrom P-A *et al.*, 331
Tribalto M, *see* Petrucci MT *et al.*, 443
Tuomilehto J, *see* Aro A *et al.*, 127
Tuomilehto J, *see* Jalkanen L *et al.*, 163

Uusitalo U, *see* Aro A *et al.*, 127

Vadstrup S, *see* Snorgaard O *et al.*, 223
Valle R, *see* Riancho JA *et al.*, 449
Van Megen T, *see* Koopmans PP *et al.*, 139
Vega CL & Grundy SM. Studies on mechanisms for enhanced clearance of low-density lipoproteins in patients with primary hyperglyceridaemia, 5
Von der Lieth L, *see* Jess P *et al.*, 395

Waldenstrom J. In defence of the anecdotal, 1
Warrington SJ, *see* Ankier SI, 453
Wetterqvist H, *see* Caidahl K *et al.*, 265
Wiese Simonsen K, *see* Melchior T *et al.*, 53
Wilhelmsen L, *see* Landin K *et al.*, 205
Worwood M. An overview of iron metabolism at a molecular level, 381

Ytre-Arne K & Nordøy A. Simvastatin and cholestyramine in the long-term treatment of hypercholesterolaemia, 285

Zafrani ES, *see* Zuber M *et al.*, 291
Zavaroni I, Angelo Bonati P, Luchetti L, Bonora E, Buonanno G, Bergonzani M, Pagliara M, Gnudi L, Butturini L, Passeri M & Reaven GM. Habitual leisure-time physical activity is associated with differences in various risk factors for coronary heart disease, 417
Zuber M, Gherardi R, Defer G, Gaulard P, Divine M & Zafrani ES. Peripheral neuropathy, coagulopathy and nodular regenerative hyperplasia of the liver in a patient with multiple serologic auto-antibody activities and IgM β-cell lymphoma, 291

Journal of Internal Medicine 1989; **226**: 469–72

Subject Index

Acetylsalicylic acid
  in acute myocardial infarction, 303
Adrenal glands
  magnetic resonance imaging of, 463
Albumin
  plasma zinc levels in diabetes, 53
  clearance in diabetic retinopathy, 47
  excretion in diabetes, 81
Alcohol
  effect on bronchial hypersecretion, 25
  induction of villous atrophy, 133
Aluminium
  and response to erythropoietin, 311
Anaemia
  response to erythropoietin, 89
Angina pectoris
  treatment with acetylsalicylic acid, 303
  effect of xamaterol on, 331
Anticoagulation
  femoral neuropathy secondary to, 279
Apolipoprotein
  in acute myocardial infarction, 297
Arterial obstruction
  serum and urinary phosphate during, 149
Arterial stiffness
  sustained essential hypertension, 235
Arterial wall thickness
  sustained essential hypertension, 235
Arteriolar hypertrophy
  in mild hypertension, 401
Asthma
  effect of theophylline and salbutamol, 229
Atrial natriuretic factor
  determinants of levels in heart disease, 195
Atrial natriuretic peptide
  levels during change from a β-adrenoceptor blocking drug to enalapril, 143
Atrioventricular valve plane
  effects of acute myocardial infarction, 251
Autoantibodies
  activities in an IgM B-cell lymphoma, 291
Autoimmune disease
  giant cell arteritis and, 205

β-adrenoceptor blocking drugs
  abrupt change to enalapril in hypertension, 143
  lipid solubility and receptor selectivity, 17
Benzodiazepine
  poisoning, 117
Blood pressure
  calcitonin gene-related peptide levels during haemodialysis, 177
Body fluid
  composition during haemodialysis, 311
Body mass index
  population changes, 163
Bone metastases
  associated with hypocalcaemia, 449
Bowel disease
  inflammatory, rectal potential differences, 423

C-peptide
  levels in insulin-dependent diabetes, 53
Calcitonin gene-related peptide
  levels during haemodialysis, 177
Calcium
  levels associated with bone metastases, 449
Capping
  MDTC-dependent, inhibition by cigarette smoke, 73
Captopril
  interaction with indomethacin, 139
Cardiac arrhythmias
  effect of theophylline and salbutamol, 229
  magnesium deficiency in, 213
Cardiomyopathy
  dilated, effect of xamaterol, 331
Central pressures
  effect on ANF levels in heart disease, 195
Chest X-ray
  compared to echocardiography, 171
Cholestyramine
  treatment of hypercholesterolaemia, 285
Chromosome localization
  proteins mediating iron metabolism, 381
Chronic obstructive pulmonary disease
  cross-sectional epidemiological aspects, 25
  effect of theophylline and salbutamol, 229
Clinical findings
  global assessment of patients, 123
Coagulopathy
  associated with IgM B-cell lymphoma, 291
Cod liver oil
  effect on ventricular systoles, 33
Coffee
  consumption, serum cholesterol levels, 127
Collagen
  synthesis in Ehlers–Danlos syndrome, 409
Continuous ambulatory peritoneal dialysis
  levels of sulphur amino acids, 189
Core protein deficiency
  in Ehlers–Danlos syndrome 409
Coronary artery disease
  risk factors and physical activity, 417
  magnesium deficiency in, 213
  determinants of atrial natriuretic factor levels, 195
Creatinine
  serum, ventricular fibrillation prediction, 107
Crohn's colitis
  effect of cyclosporin A treatment, 157
Cyclosporin A
  treatment of psoriasis, 437
  treatment of Crohn's disease, 157

Cytomegalovirus
and neuroinfection with herpes simplex virus, 59

Dermatan sulphate proteoglycans
in Ehlers–Danlos syndrome, 409
Diabetes mellitus
delay of nephropathy by insulin, 81
fulminant severe retinopathy, 63
nephropathy, 341
plasma zinc concentrations, 53
prevalence of retinopathy in Type 1, 47
pulsatile insulin infusion, 325
Diabetic ketoacidosis
epidemiology, incidence rates, precipitating factors, mortality rates, 223
Diagnosis
clinical, in epidemic meningococcal disease, 113
Dialysis therapy
nutritional status and mortality in, 429
Diastole
filling, pulsed Doppler echocardiography, 245
Docosahexaenoic acid
protection of renal function, 437
Duodenal ulceration
in relation to personality pattern, 395
Dyspnoea
in chronic primary fibromyalgia, 265

Ebastine
efficacy and tolerability against hayfever, 453
Echocardiography
comparability of chest X-ray and, 171
pulsed Doppler, 245
effects of acute myocardial infarction on the atrioventricular plane, 251
Ehlers–Danlos syndrome
dermatan sulphate proteoglycan core proteins, 409
Eicosapentaenoic acid
protection of renal function, 437
Embolism
advanced mitral valve polapse, 433
Enalapril
β-adrenoceptor blocking drug, 143
treatment of congestive heart failure, 257
Encephalitis
and Guillain–Barre syndrome, 59
Enteropathy
related to alcohol overconsumption, 133
Epidemiology
diabetic ketoacidosis, 223
Epstein–Barr virus
in chronic infectious mononucleosis, 459
Erythropoietin
effects during haemodialysis, 311
levels during enalapril treatment, 257
therapy in anaemic haemodialysis patients, 89
Exercise capacity
effect of dyspnoea, 265
effect of erythropoietin, 311

Fats
dietary, coffee consumption and serum cholesterol, 127
Femoral neuropathy
secondary to anticoagulation, 279
Ferritin
biochemistry of, 381
serum, levels during haemodialysis, 311
serum, detection of iron deficiency, 349
Fibromyalgia
dyspnoea in chronic primary, 265
Fish oil
renal function protection in psoriasis, 437
Foetal development
effects of iron deficiency, 367
Functional status
in patients on haemodialysis, 319

Giant cell arteritis
death from, 205
Global assessment
of patients, physical findings, 123
Glomerular filtration rate
in diabetic nephropathy, 341
Glucose
plasma levels, effect of physical activity, 417
tolerance in insulin-dependent diabetes, 325
Gonadotropin
levels in multiple sclerosis, 241
Graves' disease
serum β_2-microglobulin levels, 261
Guillain–Barre syndrome
during infection with HSV and CMV, 59

Haemochromatosis
variation of transferrin saturation, 373
Haemodialysis
effects of erythropoietin, 311
functional status and personality, 319
calcitonin gene-related peptides, 177
sulphur amino acids, 189
Haemodynamics
in mild hypertension, 401
Hayfever
response to ebastine, 453
Heart disease
effect of theophylline and salbutamol, 229
Heart failure
treatment with enalapril, 257
Heart rate
left ventricular filling pattern, 245
Herpes simplex virus
neuroinfection with cytomegalovirus, 59
Human lower leg
arterial embolectomy, 149
Hyperaldosteronism
diagnosis, 463
Hyperkinetic circulation
as a pre-hypertensive stage, 401
Hyperlipidaemia
lipoprotein Lp(a), 271
Hyperlipoproteinaemia
long-term treatment, 285
Hypertension
β-adrenoceptor blocking drug and enalapril treatment, 143
femoral arterial wall stiffness, 235
hyperkinetic circulation, 401
in severe diabetic retinopathy, 47
non-pharmacological therapy, 39

Hypertriglyceridaemia
low-density lipoproteins, 5
Hypocalcaemia
and bone metastases, 449
Hypotension
during haemodialysis, 177
Hypothyroidism
serum β_2-microglobulin levels, 261

IgM
in chronic infectious mononucleosis, 459
paraprotein in Waldenström's macroglobulinaemia, 443
Indomethacin
interaction with captopril or enalapril, 139
Insulin
antibodies, in insulin-dependent diabetes, 53
response, effect of physical activity, 417
Interaction
of indomethacin with catopril or enalapril, 139
Intracerebral arteritis
death from, 205
Iron
absorption, nutritional requirements, 357
bioavailability, 357
deficiency, definition and diagnosis, 349
overload in haemodialysis, 89
requirements, 357
Iron deficiency anaemia
population groups at risk, 367
Irritable bowel syndrome
rectal potential differences, 423
Ischaemia
serum and urinary phosphate, 149
Isometric exercise
left ventricular filling pattern, 245
change to enalapril treatment, 143
Isotope technique
evaluation of effect of xamaterol, 331

Ketosis
complications of theophylline toxicity, 277
Kidney failure
calcitonin gene-related peptide levels during dialysis, 177

LDL kinetics
in primary hypertriglyceridaemia, 5
Left atrial volume
ANF levels in heart disease, 195
Left ventricle
wall motion abnormalities after myocardial infarction, 251
function, effect of xamaterol, 331
Left ventricular mass
ANF levels in coronary heart disease, 195
Left ventricular volume
ANF levels in coronary heart disease, 195
Life quality
antihypertensive drugs and, 39
Lipid solubility
β-adrenoceptor blocking drugs, 17
Lipids
acute myocardial infarction, 297
serum, in shift and day workers, 337
Lipoprotein
Lp(a) levels in hyperlipidaemia, 271
levels in shift and day workers, 337
Low-density lipoproteins
in primary hypertriglyceridaemia, 5
Lymphocyte
function, impairment by cigarette smoke, 73
levels in chronic infectious mononucleosis, 459

Macroglobulinaemia
in Waldenström's disease, 443
Magnesium
deficiency in coronary artery disease, 213
Magnetic resonance imaging
of adrenal glands, 463
Malignant disease
in adult nephrotic syndrome, 201
Mean arterial pressure
progression of chronic renal failure, 183
Meningitis
accuracy of clinical diagnosis, 113
Metabolic control
diabetic retinopathy, 47
Minnesota Multiphasic Personality Inventory
use in duodenal ulcer patients, 395
Mitral valve
prolapse, thromboembolism and, 433
regurgitation, thromboembolism and, 433
Monoclonal IgM
B-cell lymphoma, 291
Monodansylthiacadaverine
-dependent capping inhibition, effect of cigarette smoke, 73
Mononucleosis syndrome
chronic, case report, 459
Mortality
nutritional status in dialysis, 429
Multiple sclerosis
serum sex hormone and gonadotropin levels, 241
Musculus iliacus haematoma
femoral neuropathy and anticoagulation, 279
Myocardial function
pulsed Doppler echocardiography, 245
Myocardial infarction
echocardiography and chest X-ray, 171
effect of cod liver oil, 33
displacement of the atrioventricular plane, 251
primary ventricular fibrillation, 107
serum lipids and apolipoproteins, 297
treatment with acetylsalicylic acid, 303
Myopia
severe retinopathy in diabetes, 63

Nephropathy
intensified insulin treatment, 81
diabetic, monitoring kidney function, 341
Nephrotic syndrome
occurrence of malignant disease in, 201
Nicotinic acid
treatment of hyperlipidaemia, 271
Nodular regenerative hyperplasia
of liver, IgM B-cell lymphoma, 291
Non-pharmacological methods
to replace antihypertensive drugs, 39
Nutritional status
mortality in dialysis therapy, 429

Obesity
changes in body mass index, 163

Oral polychemotherapy
in Waldenström's macroglobulinaemia, 443
Overdose
benzodiazepine, 117

Peripheral neuropathy
associated with IgM B-cell lymphoma, 291
Personality
in patients on haemodialysis, 319
pattern in duodenal ulcer patients, 395
Phlegm
in chronic obstructive lung disease, 25
Phosphate
levels during muscular ischaemia, 149
Physical activity
risk factors for coronary artery disease, 417
Poisoning
benzodiazepine, 117
Potassium
serum, prediction of ventricular fibrillation, 107
Prostrate cancer
hypocalcaemia and bone metastases, 449
Protein C
in renal allotransplantation, 101
Protein synthesis
in iron metabolism, regulation of, 381
Proteinuria
prognostic factor in chronic renal failure, 183
Psoriasis
renal function protection by cyclosporin, 437
Psychomotor performance
and iron deficiency, 367
Pulsatile insulin infusion
in insulin-dependent diabetes, 325

Receptor selectivity
of β-adrenoceptor blocking drugs, 17
Rectal potential difference
in irritable bowel syndrome, 423
Renal anaemia
respone to erythropoietin, 89
Renal failure
factors influencing progression, 183
in cyclosporin-treated psoriasis patients, 437
sulphur amino acids in plasma and muscle, 189
Rneal transplantation
perioperative protein C activity, 101
Respiration
dyspnoea in chronic primary fibromyalgia, 265
Retinopathy
fulminant severe, in diabetes, 63
in insulin-dependent diabetes, 47
Retrospective study
epidemic meningococcal disease, 113

Salbutamol
effect on cardiac arrhythmias, 229
Serum β_2-microglobulin
levels in thyroid disease, 261
Sex hormone
in women with multiple sclerosis, 241
Shiftwork
levels of serum lipids during, 337
Side-effects
effect of β-adrenoceptor blocking drugs, 17
Simvastatin
treatment of hypercholesterolaemia, 285
Small intestine
villous atrophy and alcohol consumption, 133
Smoking
chronic obstructive lung disease, 25
primary ventricular fibrillation, 107
Socio-economic status
chronic obstructive lung disease, 25
Spirometry
measurements, and dyspnoea grade, 265
Suicide
by benzodiazepine poisoning, 117
Sulphur amino acids
levels during chronic renal failure, 189
Symptoms
effect of β-adrenoceptor blocking drugs, 17

Taurine
depletion in chronic renal failure, 189
Theophylline
effect on cardiac arrhythmias, 229
toxicity, 277
Thrombosis
after renal allotransplantation, 101
in advanced mitral valve prolapse, 433
Thyroiditis
chronic lymphocytic, serum β_2-microglobulin levels, 261
Tobacco smoke
impairment of lymphocyte function, 73
Transferrin
biochemistry of, 381
Transferrin receptor
biochemistry of, 381
in assessment of iron deficiency, 349
Transferrin saturation
in haemochromatosis homozygotes, 373
Transglutaminase
inhibition during impaired lymphocyte function, 73

Ultrasound
measurement of arterial wall stiffness, 235

Vascular surgery
effect on serum and urinary phosphate, 149
Vasodilation
during haemodialysis, 177
Vasodilators
effect on blood pressure during haemodialysis, 177
Ventricular extrasystoles
effect of cod liver oil, 33
Ventricular fibrillation
in acute myocardial infarction, 107
Villous atrophy
and chronic alcohol consumption, 133

Waldenström's disease
oral polychemotherapeutic treatment, 443

Xamaterol
angina pectoris and dilated cardiomyopathy, 331

Zinc
plasma levels in diabetes, 53